Table 3 Association between clinical and pathological characteristics of study participants and survival and progression after 5-FU/oxaliplatin chemotherapy

		Survival		Progression^a
Factors	No. of patients	Relative risk of dying^b and 95% CI	P-value^c	Relative risk of progression^a and 95% CI	P-value^c
Age (years)			0.70		0.54
>60	50	1		1
51–60	26	1.27 (0.69, 2.35)		1.03 (0.60, 1.77)
⩽50	30	1.16 (0.64, 2.08)		1.30 (0.79, 2.13)
Gender			0.72		0.50
Male	79	1		1
Female	27	1.10 (0.65, 1.87)		0.84 (0.51, 1.40)
Ethnicity			0.26		0.56
Caucasian	75	1		1
Hispanic	14	0.65 (0.30, 1.38)		1.00 (0.51, 1.97)
Black	6	0.46 (0.14, 1.47)		0.70 (0.25, 1.96)
Asian	11	0.55 (0.20, 1.52)		1.47 (0.75, 2.90)
Histology			0.058		0.69
Moderate/well	77	1		1
Poor	16	1.85 (0.93, 3.66)		1.13 (0.61, 2.11)
Unknown	13
Side of tumour			0.077		0.51
Left	71	1		1
Right	34	1.55 (0.93, 2.60)		1.16 (0.74, 1.82)
Unknown	1
Number of metastatic sites			0.95		0.60
1	46	1		1
2	41	0.94 (0.57, 1.63)		0.81 (0.51, 1.30)
3+	19	0.91 (0.46, 1.78)		0.79 (0.43, 1.47)
Performance status			<0.001		0.001
0–1	78	1		1
2	28	3.46 (1.99, 6.01)		2.15 (1.30, 3.57)

5-FU=5-fluorouracil; CI=confidence interval.
^aTime to progression was calculated from the time that patient started treatment until the patient was taken off study. If the relative risk is greater than 1, the relative risk can be thought as the average increased risk of progression at any point in time compared to the reference group. The group with the ratio equal to 1 is the reference group.
^bIf the relative risk is greater than 1, the relative risk can be thought as the average increased risk of dying at any point in time compared to the reference group. The group with the ratio equal to 1 is the reference group.
^cP-value based on log-rank test.

Quick links

Search